Exchange & Returns Information
Review Details
(0)
| Generic For | REVLIMID |
|---|---|
| Active Ingredient | LENALIDOMIDE |
| Strength | 5MG |
| Manufacturer | CIPLA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 3 BOXES - 30 CAPSULES | $ 1.83 | $ 55.00 |
$ 46.75
Apply ZARVY26 (-15%)
You save $ 8.25
|
||
| 6 BOXES - 60 CAPSULES | $ 1.87 | $ 112.00 |
$ 95.20
Apply ZARVY26 (-15%)
You save $ 16.80
|
||
| ★ Best Value 9 BOXES - 90 CAPSULES | $ 1.74 |
5% $ 165.00
$ 157.00
|
$ 133.45
Apply ZARVY26 (-15%)
You save $ 23.55
|
Reference information will be available soon.
Lenmid 5 is an oral immunomodulatory agent containing lenalidomide 5mg, primarily used in hematologic malignancies such as multiple myeloma, myelodysplastic syndromes (MDS), and certain lymphomas. It works by binding to cereblon, a key substrate receptor of the E3 ubiquitin ligase complex, leading to degradation of oncogenic proteins and restoration of immune surveillance through enhanced T-cell and NK cell activity. The compound also exerts anti-angiogenic effects, contributing to its broad-spectrum efficacy in blood cancers.
AntiCancerDrugs > Multiple Myeloma
Lenmid 5 is indicated as part of first-line and relapsed multiple myeloma therapy in combination with dexamethasone or proteasome inhibitors like bortezomib. It inhibits malignant plasma cell proliferation and triggers apoptosis via cereblon-mediated degradation of Ikaros and Aiolos. It is also a standard agent for maintenance therapy post-autologous stem cell transplant, helping delay disease progression and improve long-term survival outcomes.
Myelodysplastic Syndrome (MDS)
For transfusion-dependent anemia associated with low- or intermediate-1-risk MDS with 5q deletion, Lenmid 5 improves erythropoiesis by restoring bone marrow hematopoietic function. It represents the first FDA-approved targeted therapy for this subset and significantly reduces transfusion burden while inducing cytogenetic remission in many patients.
Mantle Cell Lymphoma (MCL)
In relapsed or refractory MCL cases, especially after two prior lines of therapy including bortezomib, Lenmid 5 serves as a potent second-line or salvage option. It can be used as monotherapy or combined with monoclonal antibodies, offering disease control in heavily pretreated populations.
Additional Lymphoid Malignancies
Lenmid 5 is also employed off-label in certain cases of chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). Its immunomodulatory and anti-tumor synergy with rituximab has demonstrated clinical benefit in these indolent lymphomas.
Multiple Myeloma
In combination with dexamethasone: 25 mg once daily on Days 1–21 of a 28-day cycle
Maintenance post-auto HSCT: Start at 10 mg daily Days 1–28, then titrate to 15 mg daily if tolerated
Duration: Continue until progression or unacceptable toxicity
Notes: Mobilize stem cells within 4 cycles for transplant candidates; start maintenance only after adequate count recovery
Myelodysplastic Syndrome (5q deletion)
Dose: 10 mg orally once daily, continuous
Adjust based on blood counts and clinical response
Use: For transfusion-dependent anemia in MDS with 5q deletion
Mantle Cell Lymphoma
Dose: 25 mg orally on Days 1–21 of each 28-day cycle
Continue until disease progression or unacceptable adverse effects
Use: For relapsed/refractory MCL after ≥2 prior regimens, including bortezomib
Follicular Lymphoma / Marginal Zone Lymphoma
Dose: 20 mg orally once daily on Days 1–21 of a 28-day cycle
Duration: Up to 12 cycles in combination with rituximab
Use: For previously treated FL or MZL with CD20+ expression
Store at a temperature below 25°C in a dry environment. Protect from light and moisture. Keep in original packaging until use. Keep out of reach of children.
- Common: Fatigue, neutropenia, thrombocytopenia, rash, diarrhea - Serious: Venous thromboembolism, tumor lysis syndrome, hepatotoxicity, SJS/TEN - Long-term: Risk of secondary malignancies (AML/MDS), persistent cytopenias
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
